share_log

8-K: Current report

8-K: Current report

8-K：重大事件
美股SEC公告 ·  08/21 13:22
Moomoo AI 已提取核心信息
On August 20, 2024, SeaStar Medical Holding Corporation entered into an At The Market Offering Agreement with H.C. Wainwright & Co., LLC, to sell shares of its common stock through an 'at the market' offering program. The sales will be made on the Nasdaq Capital Market or other trading markets for the company's stock. SeaStar Medical will pay a 3.0% commission on gross sales to Wainwright and provide indemnification and expense reimbursement. The agreement includes customary representations, warranties, and conditions, and the company has the discretion to suspend offers or not sell any shares. The offering will continue until either party terminates the agreement. The shares will be issued under the company's shelf registration statement and related prospectus supplements. A prospectus supplement covering the sale of shares worth $25 million was filed with the SEC on the same date. The ATM Agreement is detailed in Exhibit 10.1 of the current report filed with the SEC, and legal opinions from Dorsey & Whitney LLP regarding the share issuance are included as Exhibit 5.1.
On August 20, 2024, SeaStar Medical Holding Corporation entered into an At The Market Offering Agreement with H.C. Wainwright & Co., LLC, to sell shares of its common stock through an 'at the market' offering program. The sales will be made on the Nasdaq Capital Market or other trading markets for the company's stock. SeaStar Medical will pay a 3.0% commission on gross sales to Wainwright and provide indemnification and expense reimbursement. The agreement includes customary representations, warranties, and conditions, and the company has the discretion to suspend offers or not sell any shares. The offering will continue until either party terminates the agreement. The shares will be issued under the company's shelf registration statement and related prospectus supplements. A prospectus supplement covering the sale of shares worth $25 million was filed with the SEC on the same date. The ATM Agreement is detailed in Exhibit 10.1 of the current report filed with the SEC, and legal opinions from Dorsey & Whitney LLP regarding the share issuance are included as Exhibit 5.1.
2024年8月20日，SeaStar医疗控股公司与H.C. Wainwright & Co., LLC签订了《现货市场交易协议》，通过“现货市场”推出计划，出售其普通股份。销售将在纳斯达克资本市场或公司股票的其他交易市场进行。SeaStar医疗将向Wainwright支付3.0%的销售总额佣金，并提供赔偿和费用补偿。协议中包括习惯的陈述、担保和条件，公司有权决定是否暂停报价或不出售任何股份。这一发行将持续进行，直到任一方终止协议。股份将根据公司的存续注册声明和相关的招股说明进行发行。文件显示，用于出售价值为2500万美元的股份的招股说明补充资料已于同一日期提交给美国证券交易委员会。有关ATM协议的详细信息可以在提交给美国证券交易委员会的当前报告的附件10.1中找到，关于股份发行的律师意见在附件5.1中。
2024年8月20日，SeaStar医疗控股公司与H.C. Wainwright & Co., LLC签订了《现货市场交易协议》，通过“现货市场”推出计划，出售其普通股份。销售将在纳斯达克资本市场或公司股票的其他交易市场进行。SeaStar医疗将向Wainwright支付3.0%的销售总额佣金，并提供赔偿和费用补偿。协议中包括习惯的陈述、担保和条件，公司有权决定是否暂停报价或不出售任何股份。这一发行将持续进行，直到任一方终止协议。股份将根据公司的存续注册声明和相关的招股说明进行发行。文件显示，用于出售价值为2500万美元的股份的招股说明补充资料已于同一日期提交给美国证券交易委员会。有关ATM协议的详细信息可以在提交给美国证券交易委员会的当前报告的附件10.1中找到，关于股份发行的律师意见在附件5.1中。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息